• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by InMode Ltd. (Amendment)

    2/14/22 4:10:11 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $INMD alert in real time by email
    SC 13G/A 1 d211221sc13ga1.htm AMENDMENT NO. 1

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 1) *

     

     

     

    InMode Ltd.

    (Name of Issuer)

     

    Ordinary Shares, par value NIS 0.01 per share

    (Title of Class of Securities)

     

    M5425M 103

    (CUSIP Number)

     

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)

     

    o Rule 13d-1(c)

     

    x Rule 13d-1(d)

     

    ______________________________

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liabilities of that section of the Exchange Act but shall be subject to all other provisions of the Exchange Act (however, see the Notes).

     

     

     

      
     

     

    CUSIP No. M5425M 103

     

    1.

    NAME OF REPORTING PERSON

     

    BoomerangFX International SRL

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       o

    (b)       o

     

    3. SEC USE ONLY:
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION:

     

    Barbados

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER:

     

    0 shares

    6.

    SHARED VOTING POWER:

     

    8,123,440 shares

    7.

    SOLE DISPOSITIVE POWER:

     

    0 shares

    8.

    SHARED DISPOSITIVE POWER:

     

    8,123,440 shares

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

    8,123,440 shares

    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):  o
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

     

    9.79%(1)

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

    CO

     

    (1) Based on 82,978,115 ordinary shares outstanding as of December 31, 2021 reported on the Issuer’s annual report on Form 20-F filed with the Securities and Exchange Commission on February 10, 2022.

     

     Page 2 of 11 
     

     

    CUSIP No. M5425M 103

     

    1.

    NAME OF REPORTING PERSON

     

    I.V.C. Enterprises SRL

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       o

    (b)       o

     

    3. SEC USE ONLY:
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION:

     

    Barbados

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER:

     

    0 shares

    6.

    SHARED VOTING POWER:

     

    8,123,440 shares

    7.

    SOLE DISPOSITIVE POWER:

     

    0 shares

    8.

    SHARED DISPOSITIVE POWER:

     

    8,123,440 shares

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

    8,123,440 shares

    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): o
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

     

    9.79%(1)

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

    CO

     

    (1) Based on 82,978,115 ordinary shares outstanding as of December 31, 2021 reported on the Issuer’s annual report on Form 20-F filed with the Securities and Exchange Commission on February 10, 2022.

     

     Page 3 of 11 
     

     

    CUSIP No. M5425M 103

     

    1.

    NAME OF REPORTING PERSON

     

    NEV Property Investments SRL

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       o

    (b)       o

     

    3. SEC USE ONLY:
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION:

     

    Barbados

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER:

     

    0 shares

    6.

    SHARED VOTING POWER:

     

    8,123,440 shares

    7.

    SOLE DISPOSITIVE POWER:

     

    0 shares

    8.

    SHARED DISPOSITIVE POWER:

     

    8,123,440 shares

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

    8,123,440 shares

    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): o
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

     

    9.79%(1)

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

    CO

     

    (1) Based on 82,978,115 ordinary shares outstanding as of December 31, 2021 reported on the Issuer’s annual report on Form 20-F filed with the Securities and Exchange Commission on February 10, 2022.

     

     Page 4 of 11 
     

     

    CUSIP No. M5425M 103

     

    1.

    NAME OF REPORTING PERSON

     

    Dr. Stephen Mulholland

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       o

    (b)       o

     

    3. SEC USE ONLY:
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION:

     

    Canada

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER:

     

    0 shares

    6.

    SHARED VOTING POWER:

     

    8,123,440 shares

    7.

    SOLE DISPOSITIVE POWER:

     

    0 shares

    8.

    SHARED DISPOSITIVE POWER:

     

    8,123,440 shares

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

    8,123,440 shares

    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): o
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

     

    9.79%(1)

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

    IN

     

    (1) Based on 82,978,115 ordinary shares outstanding as of December 31, 2021 reported on the Issuer’s annual report on Form 20-F filed with the Securities and Exchange Commission on February 10, 2022.

     

     Page 5 of 11 
     

     

    CUSIP No. M5425M 103

     

    Item 1.

     

    (a)Name of Issuer:

     

    InMode Ltd. (the “Issuer”).

     

    (b)Address of Issuer’s Principal Executive Offices:

     

    Tavor Building, Sha’ar Yokneam

    P.O. Box 533

    Yokneam 2069206, Israel

     

    Item 2.

     

    (a)Name of Person Filing:

     

    This filing is being made jointly by BoomerangFX International SRL (“BoomerangFX”), I.V.C. Enterprises SRL (“I.V.C.”), NEV Property Investments SRL (“NEV”) and Dr. Stephen Mulholland (“Dr. Mulholland”), each of whom is sometimes referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

     

    BoomerangFX is a Barbados society with restricted liability and a wholly owned direct subsidiary of I.V.C., which is a Barbados society with restricted liability and a wholly owned direct subsidiary of NEV, a Barbados society with restricted liability. NEV is wholly owned by Dr. Mulholland. Each of the Reporting Persons may be deemed to beneficially own the ordinary shares owned directly by BoomerangFX.

     

    Dr. Mulholland, in his capacity as sole member of NEV, has the power to vote and dispose of the shares of NEV. NEV, in its capacity as sole member of I.V.C., has the power to vote and dispose of the shares of I.V.C. I.V.C., in its capacity as sole member of BoomerangFX, has the power to vote and dispose of the shares of BoomerangFX.

     

    (b)Address of Principal Business Office or, if none, Residence:

     

    BoomerangFX International SRL

    No. 15 Maxwell Main Road
    Christ Church, Barbados BB15042

     

    I.V.C. Enterprises SRL
    No. 15 Maxwell Main Road
    Christ Church, Barbados BB15042

     

    NEV Property Investments SRL
    No. 15 Maxwell Main Road
    Christ Church, Barbados BB15042

     

    Dr. Stephen Mulholland

    c/o BoomerangFX International SRL
    No. 15 Maxwell Main Road
    Christ Church, Barbados BB15042

     

     Page 6 of 11 
     

     

    CUSIP No. M5425M 103

     

    (c)Citizenship:

     

    BoomerangFX is organized under the laws of Barbados.

     

    I.V.C. is organized under the laws of Barbados.

     

    NEV is organized under the laws of Barbados.

     

    Dr. Mulholland is a citizen of Canada.

     

    (d)Title of Class of Securities:

     

    Ordinary shares, NIS 0.01 par value per share

     

    (e)CUSIP Number:

     

    M5425M 103

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

    (b) o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c) o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

    (d) o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

     

    (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (f) o An employee benefit plan or endowment fund in accordance with §240.13d-1(b) (1)(ii)(F);

     

    (g) o A parent holding company or control person in accordance with §240.13d-1(b) (1)(ii)(G);

     

    (h) o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j) o A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

    (k) o Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: Not applicable.

     

     Page 7 of 11 
     

     

    CUSIP No. M5425M 103

     

    Item 4.Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

     

      A. BoomerangFX International SRL
        (a) Amount beneficially owned:  8,123,440
        (b) Percent of class: 9.79%.  The percentages used herein and in the rest of this Schedule 13G/A are calculated based upon 82,978,115 ordinary shares outstanding as of December 31, 2021 reported on the Issuer’s annual report on Form 20-F filed with the Securities and Exchange Commission on February 10, 2022.
        (c) (i) Sole power to vote or direct the vote:  -0-
          (ii) Shared power to vote or direct the vote:  8,123,440
          (iii) Sole power to dispose or direct the disposition of:  -0-
          (iv) Shared power to dispose or direct the disposition of:  8,123,440

     

     

      B. I.V.C. Enterprises SRL
        (a) Amount beneficially owned:  8,123,440
        (b) Percent of class: 9.79%
        (c) (i) Sole power to vote or direct the vote:  -0-
          (ii) Shared power to vote or direct the vote:  8,123,440
          (iii) Sole power to dispose or direct the disposition of:  -0-
          (iv) Shared power to dispose or direct the disposition of:  8,123,440

     

     

      C. NEV Property Investments SRL
        (a) Amount beneficially owned:  8,123,440
        (b) Percent of class: 9.79%
        (c) (i) Sole power to vote or direct the vote:  -0-
          (ii) Shared power to vote or direct the vote:  8,123,440
          (iii) Sole power to dispose or direct the disposition of:  -0-
          (iv) Shared power to dispose or direct the disposition of:  8,123,440

     

     

      D. Dr. Stephen Mulholland
        (a) Amount beneficially owned:  8,123,440
        (b) Percent of class: 9.79%
        (c) (i) Sole power to vote or direct the vote:  -0-
          (ii) Shared power to vote or direct the vote:   8,123,440
          (iii) Sole power to dispose or direct the disposition of:  -0-
          (iv) Shared power to dispose or direct the disposition of:  8,123,440

     

     Page 8 of 11 
     

     

    CUSIP No. M5425M 103

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certifications.

     

    Not applicable.

     

     Page 9 of 11 
     

     

    CUSIP No. M5425M 103

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2022

     

     

    BOOMERANGFX INTERNATIONAL SRL

     

    /s/ Neal Griffith

     

    Name: Neal Griffith

    Title: Manager

     

     

    DR. STEPHEN MULHOLLAND

     

    /s/ Dr. Stephen Mulholland

     

    Name: Dr. Stephen Mulholland

     

       
     

    I.V.C. ENTERPRISES SRL

     

    /s/ Neal Griffith

     

    Name: Neal Griffith

    Title: Manager

     

       
     

    NEV PROPERTY INVESTMENTS SRL

     

    /s/ Neal Griffith

     

    Name: Neal Griffith

    Title: Manager

     

    Exhibit(s):

     

    1.            Joint Filing Agreement

     

     Page 10 of 11 
     

     

    CUSIP No. M5425M 103

     

    EXHIBIT 1

     

    JOINT FILING AGREEMENT

     

    In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: February 14, 2022

     

     

    BOOMERANGFX INTERNATIONAL SRL

     

    /s/ Neal Griffith

     

    Name: Neal Griffith

    Title: Manager

     

     

    DR. STEPHEN MULHOLLAND

     

    /s/ Dr. Stephen Mulholland

     

    Name: Dr. Stephen Mulholland

     

       
     

    I.V.C. ENTERPRISES SRL

     

    /s/ Neal Griffith

     

    Name: Neal Griffith

    Title: Manager

     

       
     

    NEV PROPERTY INVESTMENTS SRL

     

    /s/ Neal Griffith

     

    Name: Neal Griffith

    Title: Manager

     

     

     

    Page 11 of 11

     

     

     

    Get the next $INMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INMD

    DatePrice TargetRatingAnalyst
    4/29/2025Buy → Neutral
    BTIG Research
    4/28/2025$22.00 → $16.00Outperform → Neutral
    Robert W. Baird
    10/17/2024$25.00Buy
    BTIG Research
    7/23/2024$21.00 → $19.00Buy → Hold
    Jefferies
    11/3/2023$52.00 → $24.00Buy → Neutral
    UBS
    10/13/2023$55.00 → $22.00Buy → Hold
    Canaccord Genuity
    3/29/2023$40.00Buy
    UBS
    2/17/2023Buy → Hold
    Needham
    More analyst ratings

    $INMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    InMode downgraded by BTIG Research

    BTIG Research downgraded InMode from Buy to Neutral

    4/29/25 8:06:22 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded InMode from Outperform to Neutral and set a new price target of $16.00 from $22.00 previously

    4/28/25 1:56:11 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BTIG Research initiated coverage on InMode with a new price target

    BTIG Research initiated coverage of InMode with a rating of Buy and set a new price target of $25.00

    10/17/24 7:41:34 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    SEC Filings

    View All

    SEC Form 6-K filed by InMode Ltd.

    6-K - InMode Ltd. (0001742692) (Filer)

    11/5/25 7:00:08 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 6-K filed by InMode Ltd.

    6-K - InMode Ltd. (0001742692) (Filer)

    9/18/25 7:30:09 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 6-K filed by InMode Ltd.

    6-K - InMode Ltd. (0001742692) (Filer)

    7/30/25 7:01:14 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    InMode Reports Third Quarter 2025 Financial Results: Quarterly Revenue of $93.2 Million, 78% Gross Margins

    YOKNEAM, Israel, Nov. 5, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights: Quarterly GAAP revenues of $93.2 million, compared to $130.2 million in the third quarter of 2024, which included $31.9 million of pre-order sales.Quarterly revenues from consumables and service of $19.9 million, an increase of 26% compared to the third quarter of 2024.GAAP operating income of $20.9 million. *Non-GAAP operating income was $23.6 million.Total cash position of $532.3 million as of September 30, 2025, incl

    11/5/25 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode Appoints Michael Dennison as President of North America

    IRVINE, Calif., Nov. 3, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, has appointed Michael Dennison, most recently Vice President of Sales, as President of North America.  Dennison has held nearly every sales position in the aesthetic medical device industry, consistently producing at the highest level in each. With close to a decade of leadership experience at InMode, Dennison has advanced through roles from District Sales Manager to Vice President of Sales, driving national revenue growth, expanding market shar

    11/3/25 8:05:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode to Participate in Upcoming Investor Conferences

    YOKNEAM, Israel, Oct. 30, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced the participation in the following investor conferences in November: UBS Global Healthcare Conference Presenter: Yair Malca, Chief Financial Officer Format: In-person one-on-one meetings Location: Palm Beach Gardens, FL When: Monday, November 10 Jefferies Global Healthcare Conference Presenter: Moshe Mizrahy, Chief Executive Officer Format: In-person fireside chat moderated by Matt Taylor, Senior Equity Analyst, and one-on-one meetings Location: London, U.K. When: Tuesday, November 18, Fireside Chat at 4:00 pm GMT A live webcast of the prese

    10/30/25 8:30:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Leadership Updates

    Live Leadership Updates

    View All

    InMode Appoints Michael Dennison as President of North America

    IRVINE, Calif., Nov. 3, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, has appointed Michael Dennison, most recently Vice President of Sales, as President of North America.  Dennison has held nearly every sales position in the aesthetic medical device industry, consistently producing at the highest level in each. With close to a decade of leadership experience at InMode, Dennison has advanced through roles from District Sales Manager to Vice President of Sales, driving national revenue growth, expanding market shar

    11/3/25 8:05:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by InMode Ltd. (Amendment)

    SC 13G/A - InMode Ltd. (0001742692) (Subject)

    2/13/24 4:31:18 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by InMode Ltd. (Amendment)

    SC 13G/A - InMode Ltd. (0001742692) (Subject)

    2/13/24 4:25:40 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by InMode Ltd.

    SC 13G - InMode Ltd. (0001742692) (Subject)

    2/6/24 9:36:39 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Financials

    Live finance-specific insights

    View All

    InMode Reports Third Quarter 2025 Financial Results: Quarterly Revenue of $93.2 Million, 78% Gross Margins

    YOKNEAM, Israel, Nov. 5, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights: Quarterly GAAP revenues of $93.2 million, compared to $130.2 million in the third quarter of 2024, which included $31.9 million of pre-order sales.Quarterly revenues from consumables and service of $19.9 million, an increase of 26% compared to the third quarter of 2024.GAAP operating income of $20.9 million. *Non-GAAP operating income was $23.6 million.Total cash position of $532.3 million as of September 30, 2025, incl

    11/5/25 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode to Report Third Quarter 2025 Financial Results and Hold Conference Call on November 5, Expects Q3 Revenue Between $92.5M-$93.0M, Reiterates FY 2025 Guidance Between $365M-$375M

    Conference call to be held on Wednesday, November 5, 2025, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Oct. 9, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the third quarter 2025 before the Nasdaq market opens on Wednesday, November 5, 2025. InMode is currently finalizing its financial results for the third quarter of 2025. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of InMode's financial results for such period, subject to final adjustments and other developments that may aris

    10/9/25 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Return Capital to the Shareholders

    Believes the Board Should Approve and Execute a 10% Buyback in Q4 2025 and Another 10% Buyback in Q1 2026 Maintains Board Has Legal and Fiduciary Duty to Act in Best Interests of Shareholders  MIAMI, Sept. 9, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of InMode Ltd. (NYSE: INMD) ("InMode"), today sent a letter to the Board of Directors of InMode (the "Board") urging the Board to return capital to shareholders.  The letter can be downloaded here The full text of the letter follows: September 9th, 2025 To the Board Members of InMode: In

    9/9/25 8:15:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care